Compare VZLA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | HRMY |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | N/A | 2020 |
| Metric | VZLA | HRMY |
|---|---|---|
| Price | $3.87 | $36.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.00 | ★ $49.75 |
| AVG Volume (30 Days) | ★ 13.5M | 595.8K |
| Earning Date | 12-12-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | N/A | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $16.28 |
| P/E Ratio | ★ N/A | $11.97 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $1.69 | $25.52 |
| 52 Week High | $7.19 | $40.87 |
| Indicator | VZLA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 47.62 |
| Support Level | $3.58 | $36.17 |
| Resistance Level | $5.47 | $38.21 |
| Average True Range (ATR) | 0.46 | 1.29 |
| MACD | -0.25 | 0.01 |
| Stochastic Oscillator | 8.17 | 27.30 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.